ROBOSENSE
22.8.2019 16:57:11 CEST | Business Wire | Press release
RoboSense, the leading supplier of LiDAR perception system solutions, and Aidrivers, the UK's leading provider of autonomous mobility solutions for industrial applications announced today a partnership in system integration. Aidrivers will integrate RoboSense Smart LiDAR Sensor System into their own Autonomous Driving Systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190822005468/en/
Aidrivers is delivering a fully autonomous natural navigation system that meets industrial safety standards to seaports, particularly for horizontal transportation, aimed for improving operation efficiency and leading the way in industrial autonomous mobility automation. Their solution can work under all harsh weather conditions by achieving true 3D mapping and localization for precision positioning and situation cognisance and they are using RoboSense 3D LiDAR sensor technology, which collects stable and reliable environment information at near and far distance and under different weather conditions.
“ The performance of RoboSense 3D LiDAR products in harsh weather condition is impressive. We have been testing trailer vehicles under heavy rain and harsh weather conditions and our precision positioning system based on true 3D mapping and localization systems provides accurate localization result. The point cloud data quality in rainy days is excellent and outperforming state of the art.” Aidrivers founder and CEO Dr. Rafiq Swash said, “Aidrivers is dedicated to providing safer, reliable and high-quality Ai enabled autonomous mobility solutions for industrial transportation, and the partnership with RoboSense will give a great confidence to our end users that we are providing autonomous solutions which overcome current challenges of industrial horizontal transportation. Our Ai enabled autonomous solutions are now catering to more industrial transportation industries for both indoor and outdoor in complex environment and weather conditions.”
As one of the pioneer companies to commercialize autonomous driving technology in UK, Aidrivers has been favored by industry giants in the field of autonomous port automation. Aidrivers is deploying a fleet of autonomous prime movers for the world’s leading and busiest port terminals. Aidrivers and SANY have recently partnered to deliver autonomous electric vehicles, specifically industrial horizontal transport solutions, for the Chinese market.
Video about Aidrivers and SANY’s vehicle : https://twitter.com/aidriversltd/status/1141257250629177344?s=20
In these projects, the AI enabled autonomous mobility solutions provided by Aidrivers use RoboSense's 3D LiDARs to collect rich and reliable environment perception data, conduct real-time accurate 3D object detection and tracking. Aidrivers is leading the situation cognisance with AI enabled data fusion to deliver a safer and reliable autonomous driving solutions for complex trailer vehicles under harsh weather.
“Aidrivers is driving the commercialization of autonomous driving technology for industrial transportation on a global scale. RoboSense is very pleased to collaborate with Aidrivers to build safer and robust autonomous driving solutions for major port terminals, and push for the commercialization of this technology.” RoboSense Co-founder and COO, Mark said, “Through in-depth cooperation with Aidrivers, RoboSense will continue to explore and understand the needs of industrial automation, and together with our partners, we will optimize and launch more practical LiDAR perception systems from the application perspective. ”
RoboSense's LiDAR sensors, AI Perception Algorithms and Smart LiDAR Sensor System are widely used in various types of autonomous driving scenarios. Currently, RoboSenses partners covers the world's major autonomous driving technology companies, automotive OEMs, and Tier 1 suppliers. RoboSense has always striven to optimize product performance and reliability to help autonomous driving vehicles to better cope with harsh environments and extreme conditions.
For more information please visit https://aidrivers.ai/ and https://www.robosense.ai/
View source version on businesswire.com: https://www.businesswire.com/news/home/20190822005468/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom